Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
16.04
+0.83 (5.46%)
May 1, 2024, 11:39 AM EDT - Market open

Y-mAbs Therapeutics Revenue

In the year 2023, Y-mAbs Therapeutics had annual revenue of $84.82M with 29.96% growth. Revenue in the quarter ending December 31, 2023 was $23.36M, a -25.71% decrease year-over-year.

Revenue (ttm)
$84.82M
Revenue Growth
+29.96%
P/S Ratio
7.85
Revenue / Employee
$848,190
Employees
100
Market Cap
701.31M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202384.82M19.55M29.96%
Dec 31, 202265.27M30.37M87.03%
Dec 31, 202134.90M14.15M68.18%
Dec 31, 202020.75M--
Dec 31, 20190--
Dec 31, 20180--
Dec 31, 20170--
Dec 31, 20160--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Phibro Animal Health 982.01M
Varex Imaging 877.80M
Pharming Group 272.57M
Treace Medical Concepts 187.12M
OrthoPediatrics 148.73M
Autolus Therapeutics 1.70M
Revenue Rankings